# A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

> **NCT05100199** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 328 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** OnabotulinumtoxinA X
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05100199
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2022-12-02
- **Final completion:** 2022-12-02
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100199, "A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05100199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*